间充质干细胞,糖尿病足溃疡 z-bo 2020-09-29 496

　　Poor blood sugar control can cause various acute and chronic complications. According to media reports, Chu Shijian died of diabetes for many years and died of severe complications.

　　Diabetic foot is a common complication of diabetes. According to data from the International Diabetes Federation, 70% of disconnections among diabetics occur in diabetics. Diabetic feet can develop into ulcers late in the day. Diabetic foot ulcers have become a global public health problem. In the United States alone, the annual treatment costs amount to $9.1 billion. Mesenchymal stem cells are expected to be used in the treatment of diabetic wounds and have shown safety and effectiveness in preclinical and clinical trials. However, due to the shortage of commercial products, it is still difficult for clinicians to use mesenchymal stem cells.

　　South Korean biotechnology company Anterogen has developed a new drug "Allo-ASC-DFU", which contains adipose-derived mesenchymal stem cells (ADSC) used to treat diabetic foot ulcers. I want to determine the potential application of new mesenchymal stem cell drugs in the treatment of diabetic foot ulcers. This is a good reference. Researchers randomly divided 59 patients with diabetic foot ulcers into an ADSC gel complex treatment group (30) or a control group treated with polyurethane membranes (29). A similar ADSC sheet or polyurethane film is applied to diabetic wounds every week. Scratches are evaluated during weekly follow-ups of 1-12 weeks. Wagner scores were obtained during the weekly follow-up period, and the proportions of 0-2 grade patients in the Allo-ASC-DFU group and the control group were compared. The Allo-ASC-DFU group was found to recover quickly during the 1-12 week follow-up. Correspondingly, the median Kaplan-Meier time to complete the closure of the treatment group was 28.5 days and that of the control group was 63 days, a two-fold increase. in

　　In clinical trials, there were no major adverse events related to ADSC treatment. There is no doubt that the results of this phase II clinical trial will promote the progress of Anterogen's new phase III clinical trial of ADSC.

　　Anterogen's anal fistula treatment Cuepistem was approved by the Korean Food and Drug Administration in 2012. At present, Anterogen has many new ADSC drugs in clinical research. In the 8th week, the wound closure rate of the treatment group reached 73%, while that of the control group was only 47%. In the 12th week, the complete wound closure rate of the treatment group reached 82%, while that of the control group was 53%.

　　is used in the research of diabetic foot ulcer and placenta, fat MSC, umbilical cord, umbilical cord blood and bone marrow MSC. The mechanism by which MSC promotes the repair of diabetic foot ulcers is not fully understood. The possible mechanism is: after transplantation into damaged tissue, MSC differentiate into vascular endothelial cells and smooth muscle cells, thereby promoting angiogenesis. However, over time, this mechanism has been increasingly questioned: MSC promotes the production of extracellular matrix and reduces endothelial cell apoptosis, thereby promoting angiogenesis in diabetic foot. Covers various potential pro-angiogenic factors

　　MSC wounds play a role in regulating inflammation and cell transport methods are also very important for stem cell function. At this stage, the main methods of transplanting stem cells are intravascular injection and local injection. Both methods have the problems of low transplantation efficiency and short cell action time because it is difficult for stem cells to migrate to diabetic wounds. A suitable stem cell delivery system best supports stem cell adhesion, proliferation and differentiation. The polymer gel has certain anti-reactive oxygen free radical effects and can reduce stem cell apoptosis during co-transplantation. For scientists, this is a new choice. According to research, the polymer gel significantly reduces the inflammatory response mediated by TNF-α factor, stimulates the formation of human skin fibroblasts and the proliferation of microvascular endothelial cells, thereby improving the efficiency of tissue repair. It can improve and significantly reduce the healing time of diabetic ulcers. Improving the efficiency of MSC in the treatment of diabetic foot ulcers depends on the use of polymer gels.

　　Therefore, both Korea’s new fat-derived mesenchymal stem cell drugs and China’s new mesenchymal stem cell drugs use polymer gels.

　　There are reasons to believe that the joint development and interaction of material science and stem cell technology will continue to promote the application of stem cells in the treatment of diabetic foot ulcers.